Oncogene-induced senescence as an initial barrier in lymphoma development
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Acute induction of oncogenic Ras provokes cellular senescence involving the retinoblastoma (Rb) pathway, but the tumour suppressive potential of senescence in vivo remains elusive. Recently, Rb-mediated silencing of growth-promoting genes by heterochromatin formation associated with methylation of histone H3 lysine 9 (H3K9me) was identified as a critical feature of cellular senescence, which may depend on the histone methyltransferase Suv39h1. Here we show that Emicro-N-Ras transgenic mice harbouring targeted heterozygous lesions at the Suv39h1, or the p53 locus for comparison, succumb to invasive T-cell lymphomas that lack expression of Suv39h1 or p53, respectively. By contrast, most N-Ras-transgenic wild-type ('control') animals develop a non-lymphoid neoplasia significantly later. Proliferation of primary lymphocytes is directly stalled by a Suv39h1-dependent, H3K9me-related senescent growth arrest in response to oncogenic Ras, thereby cancelling lymphomagenesis at an initial step. Suv39h1-deficient lymphoma cells grow rapidly but, unlike p53-deficient cells, remain highly susceptible to adriamycin-induced apoptosis. In contrast, only control, but not Suv39h1-deficient or p53-deficient, lymphomas senesce after drug therapy when apoptosis is blocked. These results identify H3K9me-mediated senescence as a novel Suv39h1-dependent tumour suppressor mechanism whose inactivation permits the formation of aggressive but apoptosis-competent lymphomas in response to oncogenic Ras.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies in various mouse models, supported by correlative evidence from human- derived tissue samples, have underscored the tumour- suppressive role of OIS 81,120-123 .”
From Senescence and cancer — role and therapeutic opportunities (2022) · cites this paper as [120]
In the citing paper
“Oncogene-induced senescence protects against tumor initiation 34–37.”
From Cardiac glycosides are broad-spectrum senolytics (2019) · cites this paper as [36]
In the citing paper
“OIS is a powerful tumor suppressor mechanism 34–37.”
From Cardiac glycosides are broad-spectrum senolytics (2019) · cites this paper as [36]
In the citing paper
“a series of studies [22][23][24][25][26] identified senescence in several premalignant tumours, both in humans and mice.”
From Inside and out: the activities of senescence in cancer (2014) · cites this paper as [22]
In the citing paper
“| DNA damage | Eμ-Nras G12V ; ectopic Bcl2 | Doxorubicin | Lymphoma regression | 22 | | | |”
From Inside and out: the activities of senescence in cancer (2014) · cites this paper as [22]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218
Gene Action in the X-chromosome of the Mouse (Mus musculus L.)
LYON, M. F. (1961) · Nature · doi:10.1038/190372a0 · Cited by 3,978 · cited 1×
“5 with a T(6;15) translocation (see Supplementary Table 3 for details).”
BackgroundSelective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain
Bannister, A. J., Zegerman, P., Partridge, J. F., Miska, E. A., Thomas, J. O., Allshire, R. C., & Kouzarides, T. (2001) · Nature · doi:10.1038/35065138 · Cited by 2,903
Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins
Lachner, M., O'Carroll, D., Rea, S., Mechtler, K., & Jenuwein, T. (2001) · Nature · doi:10.1038/35065132 · Cited by 2,868
Self-citationRegulation of chromatin structure by site-specific histone H3 methyltransferases
Rea, S., Eisenhaber, F., O'Carroll, D., Strahl, B. D., Sun, Z.-W., Schmid, M., Opravil, S., Mechtler, K., Ponting, C. P., Allis, C. D., et al. (2000) · Nature · doi:10.1038/35020506 · Cited by 2,845 · cited 1×
“5 with a T(6;15) translocation (see Supplementary Table 3 for details).”
BackgroundSelf-citationRb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence
Narita, M., Nuñez, S., Heard, E., Narita, M., Lin, A. W., Hearn, S. A., Spector, D. L., Hannon, G. J., & Lowe, S. W. (2003) · Cell · doi:10.1016/s0092-8674(03)00401-x · Cited by 2,278
Loss of the Suv39h Histone Methyltransferases Impairs Mammalian Heterochromatin and Genome Stability
Peters, A. H. F. M., O'Carroll, D., Scherthan, H., Mechtler, K., Sauer, S., Schöfer, C., Weipoltshammer, K., Pagani, M., Lachner, M., Kohlmaier, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00542-6 · Cited by 1,766
Self-citationSibling rivalry in the E2F family
Trimarchi, J. M., & Lees, J. A. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm714 · Cited by 1,158
A Senescence Program Controlled by p53 and p16INK4a Contributes to the Outcome of Cancer Therapy
Schmitt, C. A., Fridman, J. S., Yang, M., Lee, S., Baranov, E., Hoffman, R. M., & Lowe, S. W. (2002) · Cell · doi:10.1016/s0092-8674(02)00734-1 · Cited by 1,050
Self-citation
Cited by
Items 101–200 of 1,000
Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance
Wilting, R. H., & Dannenberg, J.-H. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.01.008 · Cited by 303
Coppé, J.-P., Patil, C. K., Rodier, F., Sun, Y., Muñoz, D. P., Goldstein, J., Nelson, P. S., Desprez, P.-Y., & Campisi, J. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060301 · Cited by 302
“lesions from progressing to malignant cancers [16–19].”
Canonical and non-canonical JAK–STAT signaling
Li, W. X. (2008) · Trends in Cell Biology · doi:10.1016/j.tcb.2008.08.008 · Cited by 290
miR-22 represses cancer progression by inducing cellular senescence
Xu, D., Takeshita, F., Hino, Y., Fukunaga, S., Kudo, Y., Tamaki, A., Matsunaga, J., Takahashi, R.-U., Takata, T., Shimamoto, A., et al. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201010100 · Cited by 289
Molecular functions and biological roles of hepatitis B virus x protein
Tang, H., Oishi, N., Kaneko, S., & Murakami, S. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00299.x · Cited by 282
Oncogene-induced senescence and tumour control in complex biological systems
Galluzzi, L., & Vitale, I. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-018-0102-y · Cited by 242
p21 transcription is regulated by differential localization of histone H2A.Z
Gévry, N., Chan, H. M., Laflamme, L., Livingston, D. M., & Gaudreau, L. (2007) · Genes & Development · doi:10.1101/gad.1545707 · Cited by 266
Immune Senescence, Immunosenescence and Aging
Lee, K.-A., Flores, R. R., Jang, I. H., Saathoff, A., & Robbins, P. D. (2022) · Frontiers in Aging · doi:10.3389/fragi.2022.900028 · Cited by 283
“The programmed VIS response is morphologically and transcriptionally indistinguishable from other types of senescence including oncogene-induced senescence (OIS) (Serrano et al., 1997; Braig et al., 2005).”
BackgroundKosar, M., Bartkova, J., Hubackova, S., Hodny, Z., Lukas, J., & Bartek, J. (2011) · Cell Cycle · doi:10.4161/cc.10.3.14707 · Cited by 283
Cellular senescence in development, regeneration and disease
Rhinn, M., Ritschka, B., & Keyes, W. M. (2019) · Development · doi:10.1242/dev.151837 · Cited by 279
Discovery of piperlongumine as a potential novel lead for the development of senolytic agents
Wang, Y., Chang, J., Liu, X., Zhang, X., Zhang, S., Zhang, X., Zhou, D., & Zheng, G. (2016) · Aging · doi:10.18632/aging.101100 · Cited by 274
Oncogene-Induced Senescence: Putting the Brakes on Tumor Development
Braig, M., & Schmitt, C. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4006 · Cited by 274
Self-citationThe pathways to tumor suppression via route p38
Han, J., & Sun, P. (2007) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2007.06.007 · Cited by 267
Impact of cellular senescence signature on ageing research
Sikora, E., Arendt, T., Bennett, M., & Narita, M. (2011) · Ageing Research Reviews · doi:10.1016/j.arr.2010.10.002 · Cited by 264
Cellular senescence in vivo: a barrier to tumorigenesis
Prieur, A., & Peeper, D. S. (2008) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.01.007 · Cited by 260
Genomic Instability and Cancer
Wei Dai, Y. Y. (2014) · Journal of Carcinogenesis & Mutagenesis · doi:10.4172/2157-2518.1000165 · Cited by 225
Oncogene-induced senescence: the bright and dark side of the response
Gorgoulis, V. G., & Halazonetis, T. D. (2010) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2010.07.013 · Cited by 257
Global heterochromatin loss: a unifying theory of aging?
Tsurumi, A., & Li, W. (2012) · Epigenetics · doi:10.4161/epi.20540 · Cited by 256
Cellular senescence controls fibrosis in wound healing
Jun, J.-I., & Lau, L. F. (2010) · Aging · doi:10.18632/aging.100201 · Cited by 255
“Compelling evidence has established cellular senescence as an important mechanism of tumor suppression, which functions by blocking the proliferation of damaged cells that may be at risk of oncogenic transformation [3,9,13,29].”
BackgroundSuppressing Cancer: The Importance of Being Senescent
Campisi, J. (2005) · Science · doi:10.1126/science.1116801 · Cited by 249
Cellular senescence and cancer treatment
Schmitt, C. A. (2007) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.08.005 · Cited by 254
Self-citationSenescent tumor cells lead the collective invasion in thyroid cancer
Kim, Y. H., Choi, Y. W., Lee, J., Soh, E. Y., Kim, J.-H., & Park, T. J. (2017) · Nature Communications · doi:10.1038/ncomms15208 · Cited by 253
Physiological and pathological consequences of cellular senescence
Burton, D. G. A., & Krizhanovsky, V. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1691-3 · Cited by 253
“important for preventing lymphoma development and contribute to response to therapy [47, 51].”
BackgroundHoenicke, L., & Zender, L. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs124 · Cited by 248
Essential role for premature senescence of myofibroblasts in myocardial fibrosis
Meyer, K., Hodwin, B., Ramanujam, D., Engelhardt, S., & Sarikas, A. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.02.047 · Cited by 247
Interaction of KAI1 on tumor cells with DARC on vascular endothelium leads to metastasis suppression
Bandyopadhyay, S., Zhan, R., Chaudhuri, A., Watabe, M., Pai, S. K., Hirota, S., Hosobe, S., Tsukada, T., Miura, K., Takano, Y., et al. (2006) · Nature Medicine · doi:10.1038/nm1444 · Cited by 235
Cellular Senescence: Molecular Mechanisms, In Vivo Significance, and Redox Considerations
Muller, M. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2008.2104 · Cited by 238
Crosstalk between chromatin state and DNA damage response in cellular senescence and cancer.
Sulli, G., Di Micco, R., & di Fagagna, F. D. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3344 · Cited by 238
The emerging functions of histone demethylases
Agger, K., Christensen, J., Cloos, P. A., & Helin, K. (2008) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2007.12.003 · Cited by 231
Ye, X., Zerlanko, B., Kennedy, A., Banumathy, G., Zhang, R., & Adams, P. D. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.034 · Cited by 228
Senescence and Cancer: A Review of Clinical Implications of Senescence and Senotherapies
Wyld, L., Bellantuono, I., Tchkonia, T., Morgan, J., Turner, O., Foss, F., George, J., Danson, S., & Kirkland, J. L. (2020) · Cancers · doi:10.3390/cancers12082134 · Cited by 235
“Similarly, senescence has been seen in chemotherapy-treated lymphoma [64].”
BackgroundSenescence: a new weapon for cancer therapy
Acosta, J. C., & Gil, J. (2012) · Trends in Cell Biology · doi:10.1016/j.tcb.2011.11.006 · Cited by 223
Loo, T. M., Miyata, K., Tanaka, Y., & Takahashi, A. (2020) · Cancer Science · doi:10.1111/cas.14266 · Cited by 232
Actions of human telomerase beyond telomeres
Cong, Y., & Shay, J. W. (2008) · Cell Research · doi:10.1038/cr.2008.74 · Cited by 229
Suram, A., Kaplunov, J., Patel, P. L., Ruan, H., Cerutti, A., Boccardi, V., Fumagalli, M., Di Micco, R., Mirani, N., Gurung, R. L., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.132 · Cited by 227
Two-Step Senescence-Focused Cancer Therapies
Sieben, C. J., Sturmlechner, I., van de Sluis, B., & van Deursen, J. M. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.04.006 · Cited by 222
Mechanisms of transcriptional repression by histone lysine methylation
Hublitz, P., Albert, M., Hfmpeters, A., Hublitz, P., Albert, M., & Peters, A. H. F. M. (2009) · The International Journal of Developmental Biology · doi:10.1387/ijdb.082717ph · Cited by 207
Self-citationGauthier, M. L., Berman, H. K., Miller, C., Kozakeiwicz, K., Chew, K., Moore, D., Rabban, J., Chen, Y. Y., Kerlikowske, K., & Tlsty, T. D. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.10.017 · Cited by 214
Critical Functions of the Lysosome in Cancer Biology
Davidson, S. M., & Vander Heiden, M. G. (2017) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103101 · Cited by 206
Kennedy, A. L., Morton, J. P., Manoharan, I., Nelson, D. M., Jamieson, N. B., Pawlikowski, J. S., McBryan, T., Doyle, B., McKay, C., Oien, K. A., et al. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.02.020 · Cited by 213
Immunosurveillance of senescent cells: the bright side of the senescence program
Sagiv, A., & Krizhanovsky, V. (2013) · Biogerontology · doi:10.1007/s10522-013-9473-0 · Cited by 208
“…tumors and mouse models, is its ability to impose a potent barrier to tumorigenesis in response to various transforming stimuli such as activated oncogenes and DNA damage (Braig et al. 2005; Chen et al. 2005; Collado et al. 2005; Michaloglou et al. 2005; Schmitt et al. 2002; te Poele et al. 2002).”
BackgroundInfluentialBRAF Signaling and Targeted Therapies in Melanoma
Dhomen, N., & Marais, R. (2009) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2009.04.001 · Cited by 195
Chromatin structure as a mediator of aging
Feser, J., & Tyler, J. (2011) · FEBS Letters · doi:10.1016/j.febslet.2010.11.016 · Cited by 198
Cosme‐Blanco, W., Shen, M., Lazar, A. J. F., Pathak, S., Lozano, G., Multani, A. S., & Chang, S. (2007) · The EMBO Reports · doi:10.1038/sj.embor.7400937 · Cited by 205
“In mouse cells, p53 appears to be the only important senescence checkpoint (Campisi, 2005).”
BackgroundCellular senescence in cancer: from mechanisms to detection
Ou, H., Hoffmann, R., González‐López, C., Doherty, G. J., Korkola, J. E., & Muñoz‐Espín, D. (2021) · Molecular Oncology · doi:10.1002/1878-0261.12807 · Cited by 190
BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR–ABL1 kinase inhibition
Duy, C., Hurtz, C., Shojaee, S., Cerchietti, L., Geng, H., Swaminathan, S., Klemm, L., Kweon, S.-M., Nahar, R., Braig, M., et al. (2011) · Nature · doi:10.1038/nature09883 · Cited by 204
Self-citationSenescence as a therapeutic target in cancer and age-related diseases
McHugh, D., Durán, I., & Gil, J. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01074-4 · Cited by 197
Kawazu, M., Saso, K., Tong, K. I., McQuire, T., Goto, K., Son, D.-O., Wakeham, A., Miyagishi, M., Mak, T. W., & Okada, H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017830 · Cited by 198
Strategies targeting cellular senescence
Ovadya, Y., & Krizhanovsky, V. (2018) · Journal of Clinical Investigation · doi:10.1172/jci95149 · Cited by 200
Mechanisms controlling cell cycle exit upon terminal differentiation
Buttitta, L. A., & Edgar, B. A. (2007) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2007.10.004 · Cited by 201
Immune Clearance of Senescent Cells to Combat Ageing and Chronic Diseases
Song, P., An, J., & Zou, M.-H. (2020) · Cells · doi:10.3390/cells9030671 · Cited by 198
“Cellular senescence plays beneficial critical roles in numerous biological processes [5], such as tumor suppression [6,7], embryonic tissue remodeling [8] and wound healing after injury [9].”
BackgroundA comparative analysis of the cell biology of senescence and aging
Hwang, E. S., Yoon, G., & Kang, H. T. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0034-2 · Cited by 190
Size Does Matter: Why Polyploid Tumor Cells are Critical Drug Targets in the War on Cancer
Coward, J., & Harding, A. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00123 · Cited by 192
Tumor suppressor activity of the ERK/MAPK pathway by promoting selective protein degradation
Deschênes-Simard, X., Gaumont-Leclerc, M.-F., Bourdeau, V., Lessard, F., Moiseeva, O., Forest, V., Igelmann, S., Mallette, F. A., Saba-El-Leil, M. K., Meloche, S., et al. (2013) · Genes & Development · doi:10.1101/gad.203984.112 · Cited by 194
Cellular Senescence in Postmitotic Cells: Beyond Growth Arrest
Sapieha, P., & Mallette, F. A. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.03.003 · Cited by 193
Pazolli, E., Alspach, E., Milczarek, A., Prior, J., Piwnica-Worms, D., & Stewart, S. A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3386 · Cited by 192
“Thus, when activated in an incipient tumor cell, senescence is a potent tumor suppressor that must be bypassed if cells are to complete the transformation process (2).”
Assessing cell and organ senescence biomarkers
de Jesus, B. B., & Blasco, M. A. (2012) · Circulation Research · doi:10.1161/circresaha.111.247866 · Cited by 187
Bennecke, M., Kriegl, L., Bajbouj, M., Retzlaff, K., Robine, S., Jung, A., Arkan, M. C., Kirchner, T., & Greten, F. R. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.06.013 · Cited by 186
“OIS can occur in vivo in various premalignant lesions of malignant melanoma, lymphoma, prostate, and lung cancer presumably having a tumor suppressive function (Braig et al., 2005; Chen et al., 2005; Collado et al., 2005; Michaloglou et al., 2005).”
BackgroundMajumder, P. K., Grisanzio, C., O'Connell, F., Barry, M., Brito, J. M., Xu, Q., Guney, I., Berger, R., Herman, P., Bikoff, R., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.06.002 · Cited by 178
Tumor Stroma-Derived TGF-β Limits Myc-Driven Lymphomagenesis via Suv39h1-Dependent Senescence
Reimann, M., Lee, S., Loddenkemper, C., Dörr, J. R., Tabor, V., Aichele, P., Stein, H., Dörken, B., Jenuwein, T., & Schmitt, C. A. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.043 · Cited by 184
Self-citationOld dogs, new trick: classic cancer therapies activate cGAS
Yum, S., Li, M., & Chen, Z. J. (2020) · Cell Research · doi:10.1038/s41422-020-0346-1 · Cited by 181
ATR signaling can drive cells into senescence in the absence of DNA breaks
Toledo, L. I., Murga, M., Gutierrez-Martinez, P., Soria, R., & Fernandez-Capetillo, O. (2008) · Genes & Development · doi:10.1101/gad.452308 · Cited by 183
“At the organism level, cellular senescence has been recently shown to constitute a strong anti-tumoral barrier, which is activated early on during the initial steps of malignant transformation (Braig et al. 2005; Chen et al. 2005; Collado et al. 2005; Michaloglou et al. 2005).”
BackgroundAdams, P. D. (2007) · Gene · doi:10.1016/j.gene.2007.04.020 · Cited by 176
JAK signaling globally counteracts heterochromatic gene silencing
Shi, S., Calhoun, H. C., Xia, F., Li, J., Le, L., & Li, W. X. (2006) · Nature Genetics · doi:10.1038/ng1860 · Cited by 177
Resveratrol Induces Premature Senescence in Lung Cancer Cells via ROS-Mediated DNA Damage
Luo, H., Yang, A., Schulte, B. A., Wargovich, M. J., & Wang, G. Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060065 · Cited by 176
Li, Y., Choi, P. S., Casey, S. C., Dill, D. L., & Felsher, D. W. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.06.014 · Cited by 174
Loss of miRNA biogenesis induces p19Arf-p53 signaling and senescence in primary cells
Mudhasani, R., Zhu, Z., Hutvagner, G., Eischen, C. M., Lyle, S., Hall, L. L., Lawrence, J. B., Imbalzano, A. N., & Jones, S. N. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200802105 · Cited by 178
MYC—Master Regulator of the Cancer Epigenome and Transcriptome
Poole, C. J., & Van Riggelen, J. (2017) · Genes · doi:10.3390/genes8050142 · Cited by 183
TWISTing an embryonic transcription factor into an oncoprotein
Ansieau, S., Morel, A.-P., Hinkal, G., Bastid, J., & Puisieux, A. (2010) · Oncogene · doi:10.1038/onc.2010.92 · Cited by 167
Histone macroH2A isoforms predict the risk of lung cancer recurrence
Sporn, J. C., Kustatscher, G., Hothorn, T., Collado, M., Serrano, M., Muley, T., Schnabel, P., & Ladurner, A. G. (2009) · Oncogene · doi:10.1038/onc.2009.26 · Cited by 175
SIRT1 and AMPK in regulating mammalian senescence: A critical review and a working model
Wang, Y., Liang, Y., & Vanhoutte, P. M. (2011) · FEBS Letters · doi:10.1016/j.febslet.2010.11.047 · Cited by 177
Regulation of E2Fs and senescence by PML nuclear bodies
Vernier, M., Bourdeau, V., Gaumont-Leclerc, M.-F., Moiseeva, O., Bégin, V., Saad, F., Mes-Masson, A.-M., & Ferbeyre, G. (2011) · Genes & Development · doi:10.1101/gad.1975111 · Cited by 177
Wang, C.-Y., Kim, H.-H., Hiroi, Y., Sawada, N., Salomone, S., Benjamin, L. E., Walsh, K., Moskowitz, M. A., & Liao, J. K. (2009) · Science Signaling · doi:10.1126/scisignal.2000143 · Cited by 177
Bellodi, C., Kopmar, N., & Ruggero, D. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.83 · Cited by 172
Targeting Aberrant Epigenetic Networks Mediated by PRMT1 and KDM4C in Acute Myeloid Leukemia
Cheung, N., Fung, T. K., Zeisig, B. B., Holmes, K., Rane, J. K., Mowen, K. A., Finn, M. G., Lenhard, B., Chan, L. C., & So, C. W. E. (2016) · Cancer Cell · doi:10.1016/j.ccell.2015.12.007 · Cited by 175
Ye, X., Zerlanko, B., Zhang, R., Somaiah, N., Lipinski, M., Salomoni, P., & Adams, P. D. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01592-06 · Cited by 162
The lncRNA MIR31HG regulates p16INK4A expression to modulate senescence
Montes, M., Nielsen, M. M., Maglieri, G., Jacobsen, A., Højfeldt, J., Agrawal-Singh, S., Hansen, K., Helin, K., van de Werken, H. J. G., Pedersen, J. S., et al. (2015) · Nature Communications · doi:10.1038/ncomms7967 · Cited by 173
Zeng, J., Ge, Z., Wang, L., Li, Q., Wang, N., Björkholm, M., Jia, J., & Xu, D. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.10.004 · Cited by 172
The role of lysosomes in cancer development and progression
Tang, T., Yang, Z.-Y., Wang, D., Yang, X.-Y., Wang, J., Li, L., Wen, Q., Gao, L., Bian, X.-W., & Yu, S.-C. (2020) · Cell & Bioscience · doi:10.1186/s13578-020-00489-x · Cited by 169
SIRT1 suppresses the senescence-associated secretory phenotype through epigenetic gene regulation
Hayakawa, T., Iwai, M., Aoki, S., Takimoto, K., Maruyama, M., Maruyama, W., & Motoyama, N. (2015) · PLOS ONE · doi:10.1371/journal.pone.0116480 · Cited by 170
“precancerous tissues from both humans and mice and are progressively lost during cancer progression [3–7], thereby revealing senescence as a potent initial barrier to cancer progression.”
Background“Social Life” of Senescent Cells: What Is SASP and Why Study It?
Borodkina, A. V., Deryabin, P. I., Giukova, А. А., & Nikolsky, N. N. (2018) · Acta Naturae · doi:10.32607/20758251-2018-10-1-4-14 · Cited by 170
IL-6-STAT3 signaling and premature senescence
Kojima, H., Inoue, T., Kunimoto, H., & Nakajima, K. (2013) · JAK-STAT · doi:10.4161/jkst.25763 · Cited by 170
“Oncogene-induced senescence has been observed in tumor cells even at early stages.(17,18) The third type of senescence is stress-induced premature senescence.”
BackgroundPaul, R., Dorsey, J. F., & Fan, Y. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107985 · Cited by 168
Liu, B., Wang, Z., Zhang, L., Ghosh, S., Zheng, H., & Zhou, Z. (2013) · Nature Communications · doi:10.1038/ncomms2885 · Cited by 156
Nucleotide metabolism, oncogene-induced senescence and cancer
Aird, K. M., & Zhang, R. (2015) · Cancer Letters · doi:10.1016/j.canlet.2014.01.017 · Cited by 166
“OIS is considered to be a tumor suppressor mechanism in vivo [29].”
The genome and epigenome of malignant melanoma
DAHL, C., & GULDBERG, P. (2007) · APMIS · doi:10.1111/j.1600-0463.2007.apm_855.xml.x · Cited by 162
A step-by-step microRNA guide to cancer development and metastasis
Markopoulos, G. S., Roupakia, E., Tokamani, M., Chavdoula, E., Hatziapostolou, M., Polytarchou, C., Marcu, K. B., Papavassiliou, A. G., Sandaltzopoulos, R., & Kolettas, E. (2017) · Cellular Oncology · doi:10.1007/s13402-017-0341-9 · Cited by 161
HIF1α delays premature senescence through the activation of MIF
Welford, S. M., Bedogni, B., Gradin, K., Poellinger, L., Broome Powell, M., & Giaccia, A. J. (2006) · Genes & Development · doi:10.1101/gad.1471106 · Cited by 163
Rai, T. S., Cole, J. J., Nelson, D. M., Dikovskaya, D., Faller, W. J., Vizioli, M. G., Hewitt, R. N., Anannya, O., McBryan, T., Manoharan, I., et al. (2014) · Genes & Development · doi:10.1101/gad.247528.114 · Cited by 162
Systems biology of ageing and longevity
Kirkwood, T. B. L. (2011) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2010.0275 · Cited by 156
Epigenetic regulation of normal and malignant hematopoiesis
Rice, K. L., Hormaeche, I., & Licht, J. D. (2007) · Oncogene · doi:10.1038/sj.onc.1210755 · Cited by 158
Telomerase, senescence and ageing
Shawi, M., & Autexier, C. (2008) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2007.11.007 · Cited by 170
Aging by epigenetics—A consequence of chromatin damage?
Sedivy, J. M., Gowrishankar, B., & Adams, P. D. (2008) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.02.023 · Cited by 170
Yu, Y., Schleich, K., Yue, B., Ji, S., Lohneis, P., Kemper, K., Silvis, M. R., Qutob, N., van Rooijen, E., Werner-Klein, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.002 · Cited by 156
“Furthermore, these moieties also enabled T-cell lymphomagenesis in Eµ-N-Ras transgenic mice (Figure 3C), as we previously reported in this model for the absence of Suv39h1 or Trp53 alleles (Braig et al., 2005).”
BackgroundMethodResultSelf-citationThe miR-17-92 Cluster of MicroRNAs Confers Tumorigenicity by Inhibiting Oncogene-Induced Senescence
Hong, L., Lai, M., Chen, M. S., Xie, C., Liao, R., Kang, Y. J., Xiao, C., Hu, W.-Y., Han, J., & Sun, P. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1938 · Cited by 178
Banumathy, G., Somaiah, N., Zhang, R., Tang, Y., Hoffmann, J., Andrake, M., Ceulemans, H., Schultz, D., Marmorstein, R., & Adams, P. D. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01047-08 · Cited by 141
Oncogene-induced senescence results in marked metabolic and bioenergetic alterations
Quijano, C., Cao, L., Fergusson, M. M., Romero, H., Liu, J., Gutkind, S., Rovira, I. I., Mohney, R. P., Karoly, E. D., & Finkel, T. (2012) · Cell Cycle · doi:10.4161/cc.19800 · Cited by 155
Pogribny, I. P., Ross, S. A., Tryndyak, V. P., Pogribna, M., Poirier, L. A., & Karpinets, T. V. (2006) · Carcinogenesis · doi:10.1093/carcin/bgi364 · Cited by 152
The innate immune sensor Toll-like receptor 2 controls the senescence-associated secretory phenotype
Hari, P., Millar, F. R., Tarrats, N., Birch, J., Quintanilla, A., Rink, C. J., Fernández-Duran, I., Muir, M., Finch, A. J., Brunton, V. G., et al. (2019) · Science Advances · doi:10.1126/sciadv.aaw0254 · Cited by 154
COVID-19 and cellular senescence
Schmitt, C. A., Tchkonia, T., Niedernhofer, L. J., Robbins, P. D., Kirkland, J. L., & Lee, S. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00785-2 · Cited by 153
Self-citation
Metadata
- Authors
- Braig, M., Lee, S., Loddenkemper, C., Rudolph, C., Peters, A. H. F. M., Schlegelberger, B., Stein, H., Dörken, B., Jenuwein, T., & Schmitt, C. A.
- Affiliations
- Charité – Universitätsmedizin Berlin (DE)
- Medizinische Hochschule Hannover (DE)
- Research Institute of Molecular Pathology (AT)
- Max Delbrück Center (DE)
- Corresponding author
- Schmitt, Clemens A.
- ORCID
- Venue
- Nature
- Published
- 2005-08
- Volume
- 436
- Issue
- 7051
- Pages
- 660-665
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2080769506
- Cited by
- 1,220
- References
- 31
- Citations by year
- 2026: 19 · 2025: 37 · 2024: 34 · 2023: 54 · 2022: 42 · 2021: 57 · 2020: 57 · 2019: 49 · 2018: 49 · 2017: 44 · 2016: 58 · 2015: 53 · 2014: 51 · 2013: 86 · 2012: 69
- FWCI
- 43.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- MDC Repository (Max-Delbrueck-Center for Molecular Medicine) (submittedVersion)
- Funders
- European Commission
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- cellular senescence, lymphoma, oncogenic Ras, SUV39H1, H3K9 methylation, heterochromatin, retinoblastoma pathway, p53, T-cell lymphoma, tumor suppression, epigenetic silencing, histone methyltransferase
- MeSH terms
- Animals, Cell Transformation, Neoplastic, Disease Models, Animal, Heterochromatin, Lymphoma, Methylation, Methyltransferases, Mice, Transgenic, Precancerous Conditions, Genes, ras, Repressor Proteins, Biomarkers, Tumor, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Cellular Senescence, Apoptosis, Disease Progression, Transgenes, ADP-Ribosylation Factors, Chromosomal Instability, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.